Table 1 BioFINDER-2 cohort demographics

From: Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies

 

A−T− (n = 352)

A+T− (n = 184)

A+T+ (n = 231)

Non-AD (n = 110)

Age (years)

63.65 ± 14.09

71.94 ± 8.16

72.75 ± 7.40

68.63 ± 9.57

Sex, female n (% F)

182 (52)

88 (48)

125 (54)

40 (36)

Education (years)

12.70 ± 3.34

12.33 ± 3.79

12.57 ± 4.41

11.88 ± 3.58

APOEε4 carriers n (%)

110 (31)

121 (66)

168 (73)

26 (24)

MMSE

28.60 ± 1.55

27.52 ± 2.49

22.73 ± 4.98

25.85 ± 3.69

Cognitive status

Unimpaired:MCI:Dementia

262:90:0

94:70:20

22:66:143

See Extended Data Table 1

CSF Aβ42/40 (NeuroToolKit)a

0.11 ± 0.01

0.05 ± 0.01

0.04 ± 0.01

0.11 ± 0.01

Aβ-PET SUVR (flutemetamol)b

0.93 ± 0.08

1.29 ± 0.27

1.64 ± 0.23

−

Tau-PET SUVR (RO948)

1.14 ± 0.09

1.19 ± 0.09

2.1 ± 0.06

1.15 ± 0.11

PET follow-up time (years)c

2.65 ± 1.00

2.56 ± 0.97

1.90 ± 0.65

2.00 ± 0.39

  1. Data are presented as mean ± s.d. unless specified otherwise. A: Aβ status (positive or negative) based on CSF Aβ42/Aβ40 ratio; T: tau status (positive or negative) based on tau-PET uptake in a temporal meta-ROI.
  2. The non-AD group is composed of Aβ-negative patients with clinically diagnosed non-AD neurodegenerative diseases.
  3. APOEε4, apolipoprotein E genotype (carrying at least one ε4 allele).
  4. aThere are 8, 14, 23 and 5 missing values in the respective categories for which clinical assays were used to determine the Aβ status.
  5. bThere are 15, 26 and 141 missing values in the respective categories. Dementia patients do not undergo Aβ-PET, which explains the high missing frequency in A+T+ and the non-AD neurodegenerative categories.
  6. cThere are 65, 40, 87 and 53 individuals in the respective categories who did not have longitudinal data.
Back to article page